# A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)

> **NCT01632345** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 342 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Doravirine
- **DRUG:** Efavirenz
- **DRUG:** TRUVADA®
- **DRUG:** Placebo for Doravirine
- **DRUG:** Placebo for Efavirenz

## Key facts

- **NCT ID:** NCT01632345
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-12
- **Primary completion:** 2014-12-03
- **Final completion:** 2016-03-21
- **Target enrollment:** 342 (ACTUAL)
- **Last updated:** 2019-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01632345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01632345, "A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01632345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*